Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Naima Hashi"'
Autor:
Jihad Aljabban, Michael Rohr, Vincent J. Borkowski, Mary Nemer, Eli Cohen, Naima Hashi, Hisham Aljabban, Emmanuel Boateng, Saad Syed, Mohammed Mohammed, Ali Mukhtar, Dexter Hadley, Maryam Panahiazar
Publikováno v:
Journal of Pathology Informatics, Vol 13, Iss , Pp 100094- (2022)
Background: Crohn's Disease (CD) is an inflammatory disease of the gastrointestinal tract that affects millions of patients. While great strides have been made in treatment, namely in biologic therapy such as anti-TNF drugs, CD remains a significant
Externí odkaz:
https://doaj.org/article/3c6f74dc15c54fb1af07f5af121c6bb6
Autor:
Jihad Aljabban, Michael Rohr, Saad Syed, Eli Cohen, Naima Hashi, Sharjeel Syed, Kamal Khorfan, Hisham Aljabban, Vincent Borkowski, Michael Segal, Mohamed Mukhtar, Mohammed Mohammed, Emmanuel Boateng, Mary Nemer, Maryam Panahiazar, Dexter Hadley, Sajid Jalil, Khalid Mumtaz
Publikováno v:
World Journal of Gastrointestinal Oncology. 14:1856-1873
Hepatitis B virus (HBV) is a cause of hepatocellular carcinoma (HCC). Interestingly, this process is not necessarily mediated through cirrhosis and may in fact involve oncogenic processes. Prior studies have suggested specific oncogenic gene expressi
Autor:
Vincent Borkowski, Naima Hashi, Hisham Aljabban, Hajra Khan, Dexter Hadley, Maryam Panahiazar, Eli Cohen, Jihad Aljabban, Saad Syed, Mary Nemer, Michael Rohr, Ali Mukhtar, Emmanuel Boateng
Publikováno v:
American Journal of Gastroenterology. 116:S350-S350
Autor:
Naima Hashi, Maryam Panahiazar, Michael Rohr, Khalid Mumtaz, Kamal Khorfan, Emmanuel Boateng, Jihad Aljabban, Saad Syed, Mary Nemer, Sajid Jalil, Hisham Aljabban, Sharjeel Syed, Eli Cohen, Dexter Hadley
Publikováno v:
Journal of Clinical Oncology. 39:333-333
333 Background: Hepatitis B is a cause of hepatocellular carcinoma (HCC) globally, irrespective of viral loads. Interestingly, this process is not necessarily mediated through cirrhosis and may in fact involve oncogenic processes. Prior studies have
Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function
Autor:
Michael H. Zhang, Don M. Benson, Anjali Mishra, Susana Beceiro Casas, Naima Hashi, Jennifer N. Saultz, Li Chen, Gabrielle Ernst, Xiaoli Zhang, Monica Williams, Michael A. Caligiuri, Steven D. Scoville, Tiffany Hughes, Luxi Chen, Jianhua Yu, Abd Al-Rahman Traboulsi, Ansel P. Nalin, Aharon G. Freud, Bethany L. Mundy-Bosse, Kathleen McConnell
Acute myeloid leukemia (AML) can evade the mouse and human innate immune system by suppressing natural killer (NK) cell development and NK cell function. This is driven in part by the overexpression of microRNA (miR)-29b in the NK cells of AML patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d721362fb4508bcdf2215faa7264f375
https://europepmc.org/articles/PMC6202909/
https://europepmc.org/articles/PMC6202909/
Autor:
Steven D. Scoville, Jianhua Yu, Ansel P. Nalin, Michael A. Caligiuri, Luxi Chen, Bethany L. Mundy-Bosse, Aharon G. Freud, Kathleen McConnell, Li Chen, Abd Al-Rahman, Naima Hashi, Jennifer N. Saultz, Susana Beceiro Casas, Michael H. Zhang
Publikováno v:
Cancer Research. 78:4729-4729
Acute myeloid leukemia (AML) is a deadly disease in need of novel therapeutic avenues to improve outcomes. Natural killer (NK) cells have the potential to be curative in the setting of AML, although successful strategies to deploy NK cells in patient